Trial Profile
A phase II, multicenter, single-arm study of Induction therapy with LDK378 followed by surgery in patients with ALK fusion-positive Stage II/III non-small cell lung cancer.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 19 Dec 2019
Price :
$35
*
At a glance
- Drugs Ceritinib (Primary)
- Indications Adenocarcinoma; Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms SAKULA
- 17 Dec 2019 Status changed from active, no longer recruiting to discontinued.
- 10 Sep 2019 Results presented at the 20th World Conference on Lung Cancer
- 23 Apr 2018 Status changed from recruiting to active, no longer recruiting.